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Aims The immune system is strongly involved in atherosclerosis and immune regulation generally leads to attenuated ath-
erosclerosis. B- and T-lymphocyte attenuator (BTLA) is a novel co-receptor that negatively regulates the activation
of B and T cells; however, there have been no reports of BTLA and its function in atherosclerosis or cardiovascular
disease (CVD). We aimed to assess the dominant BTLA expressing leucocyte in CVD patients and to investigate




We show that BTLA is primarily expressed on B cells in CVD patients and follicular B2 cells in low-density lipopro-
tein receptor-deficient (Ldlr-/-) mice. We treated Ldlr-/- mice that were fed a western-type diet (WTD) with
phosphate-buffered saline, an isotype antibody, or an agonistic BTLA antibody (3C10) for 6 weeks. We report
here that the agonistic BTLA antibody significantly attenuated atherosclerosis. This was associated with a strong re-
duction in follicular B2 cells, while regulatory B and T cells were increased. The BTLA antibody showed similar
immunomodulating effects in a progression study in which Ldlr-/- mice were fed a WTD for 10 weeks before receiv-
ing antibody treatment. Most importantly, BTLA stimulation enhanced collagen content, a feature of stable lesions,
in pre-existing lesions.
....................................................................................................................................................................................................
Conclusion Stimulation of the BTLA pathway in Ldlr-/- mice reduces initial lesion development and increases collagen content of
established lesions, presumably by shifting the balance between atherogenic follicular B cells and atheroprotective
B cells and directing CD4þ T cells towards regulatory T cells. We provide the first evidence that BTLA is a very
promising target for the treatment of atherosclerosis.
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1. Introduction
Inflammation is a key process in the development of atherosclerosis.1
Components of both the innate and adaptive immune system contribute
significantly to the pathology of atherosclerosis. The connection be-
tween these two arms of the immune system is provided by professional
antigen presenting cells (APCs). Dendritic cells and macrophages are
well-known APCs, but nowadays the role of B cells as potent APCs is
also increasingly recognized. Next to processing and presenting antigens
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to lymphocytes, these cells provide additional stimuli in the form of co-
receptors. In fact, the activation of T cells and B cells is tightly controlled
by these immune checkpoint proteins.2 APCs have a wide-ranging vari-
ety of both stimulatory and inhibitory immune checkpoint proteins. In
general, stimulatory co-receptors are found to be atherogenic, while in-
hibitory proteins attenuate atherosclerosis.2
B- and T-lymphocyte attenuator (BTLA, also known as CD272) is a
relatively recently described co-inhibitory receptor belonging to the im-
munoglobulin superfamily. It was originally identified in search for a T
helper type 1 (Th1) marker 3 and it has been demonstrated that BTLA
interacts with herpesvirus entry mediator (HVEM).4 HVEM is part of the
tumour necrosis factor receptor superfamily and the BTLA-HVEM
interaction is an unique example of cross-talk between the immune
checkpoint proteins of both superfamilies. Ligation of HVEM to
BTLA generates an inhibitory signal, which is supported by the fact
that BTLA-deficient T and B cells are hyperresponsive.3,5,6 In addition,
BTLA-deficient mice show a marked phenotype of auto-immunity
with increased levels of auto-antibodies, spontaneous development of
autoimmune-like hepatitis,7 and increased susceptibility towards experi-
mental autoimmune encephalomyelitis.3 In humans, BTLA seems
to function similarly since BTLA cross-linking on human T cells leads
to suppressed proliferation and cytokine production.8 Moreover, in
patients with rheumatoid arthritis9 and type 1 diabetes10 functional poly-
morphisms or altered expression levels of BTLA have been found.
Hence, since its discovery as an inhibitory co-receptor, BTLA has
attracted a lot of attention as a potential target for immunotherapy.
While in oncology novel ways to block BTLA are explored,11 it has been
shown that in autoimmune or inflammatory disorders stimulation of
BTLA is a more promising option. For instance, agonistic antibodies for
BTLA have been used in experimental models of Behcet’s disease,12 ce-
rebral malaria,13 graft-versus-host disease,14 and cardiac allograft rejec-
tion.15 These data clearly indicate that the BTLA pathway is a potent
option for the treatment of autoimmune disorders. Up to date, there
have been no reports of BTLA and if it is involved in atherosclerosis or
CVD.
In this study, we therefore aimed to characterize BTLA-expressing
leucocytes in CVD patients and to investigate whether BTLA has a func-




Eleven anonymous atherosclerotic plaques and blood samples were col-
lected post-operatively from carotid or femoral endarterectomy surger-
ies performed in 2017 and 2018 at the Haaglanden Medical Center
(HMC), Westeinde, The Hague, The Netherlands. The collection of
samples was performed conform the declaration of Helsinki regarding
ethical principles for medical research involving human subjects (METC
registration number 17-046). All atherosclerotic samples were proc-
essed to single-cell suspensions as described previously.16 In short, cell
suspensions from human atherosclerotic plaques were obtained upon
digestion with collagenase IV (Gibco) and DNase (Sigma) for 30 min at
37C prior to single-cell separation through a 70 lm cell strainer. Red
blood cells in blood samples were lysed using ACK lysis buffer. All hu-
man white blood cell populations were characterized by flow cytometry
based on the expression of the pan-leucocyte marker CD45. Gating
strategies are shown where appropriate.
2.2 Animals
Female low-density lipoprotein receptor-deficient mice (Ldlr-/-) were
bred in house and kept under standard laboratory conditions. Mice were
fed a western-type diet (WTD) containing 0.25% cholesterol and 15%
cocoa butter (Special Diet Services, Witham, Essex, UK). Diet and water
were provided ad libitum. All injections were administered i.p. in a total
volume of 100mL. During the experiments, mice were weighed, and
blood samples were obtained by tail vein bleeding. At the end of experi-
ments, mice were anaesthetized by a subcutaneous injection of a cocktail
containing ketamine (40 mg/mL), atropine (50 lg/mL), and sedazine
(6.25 mg/mL). Mice were bled by femoral artery transection followed by
perfusion with phosphate-buffered saline (PBS) through the left cardiac
ventricle. All animal work was approved by the Leiden University Animal
Ethics Committee and the animal experiments were performed conform
the guidelines from Directive 2010/63/EU of the European Parliament
on the protection of animals used for scientific purposes.
2.3 In vivo experiments
Two separate diet-induced atherosclerosis experiments were per-
formed in this study; an atherosclerosis initiation and an atherosclerosis
progression experiment. For the initiation experiment, female Ldlr-/-
mice (n = 11–12/group) were fed a WTD for 6 weeks, while either re-
ceiving an i.p. injection of PBS, an appropriate Armenian hamster isotype
antibody (Innovative Research, Novi, MI; 100mg/injection), or a non-
depleting agonistic BTLA antibody15 (3C10; 100mg/injection) twice a
week. For the progression experiment, female Ldlr-/- mice (n = 11–12/
group) were first fed a WTD for 10 weeks before initiating the same
treatment with an isotype antibody or an agonistic BTLA antibody for
6 weeks. At the start of the treatment, one group of mice was sacrificed
as a baseline group. A third in vivo experiment was performed to investi-
gate the direct effect of BTLA blockade on T cells. Female Ldlr-/- mice
(n = 5–6/group) were fed a WTD for 2 weeks while, similarly as de-
scribed above, receiving i.p. injections of either PBS, isotype control,
BTLA, or receiving once a week anti-CD20 (Genentech, clone 5D2;
250mg/injection) to deplete B cells, or a combination of BTLA and anti-
CD20.
2.4 Flow cytometry
For flow cytometry analysis, Fc receptors of single-cell suspensions of
the mediastinal lymph node, spleen, blood, or peritoneum were blocked
with an unconjugated antibody against CD16/CD32. Samples were then
stained with a fixable viability marker (ThermoScientific) to select live
cells and anti-mouse fluorochrome-conjugated antibodies (see
Supplementary material online, Table SI).
For the analysis of IL-10þ B cells, single-cell suspensions were stimu-
lated for 5 h with LPS (50mg/mL), PMA (50 ng/mL), ionomycin (500 ng/
mL), and monensin (2mM). FACS analysis was performed on a
FACSCanto II (Becton Dickinson) or a Cytoflex S (Beckman Coulter)
and the acquired data were analysed using FlowJo software. Gates were
set according to unstimulated controls (only treated with monensin) or
to isotype and fluorescence minus one controls.
2.5 Serum measurements
After euthanasia, orbital blood was collected in EDTA-coated tubes.
Whole blood cell counts were analysed using the XT-2000iV haematol-
ogy analyser (Sysmex Europe GMBH, Norderstedt, Germany). Serum
was acquired by centrifugation and stored at -20C until further use. The
total cholesterol levels in serum were determined using enzymatic
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colorimetric procedures (Roche/Hitachi, Mannheim, Germany).
Precipath (Roche/Hitachi) was used as an internal standard. Total serum
titers of IgM, IgG1, IgG2c, and antigen-specific antibodies were quantified
by ELISA as previously described.17
2.6 B-cell culture
B cells were isolated from female Ldlr-/- mice using CD19þ microbeads
(Miltenyi Biotec) and cultured in complete RPMI medium in the presence
of different concentrations of the agonistic BTLA antibody or recombi-
nant murine HVEM Fc (R&D systems). After 24 h, cells were harvested
and either stained using an Annexin-V Apoptosis detection kit
(ThermoFisher) or used for routine flow cytometry.
B cells were also isolated from mice treated with PBS or the BTLA
agonistic antibody for 2 weeks. Isolated B cells were co-cultured with
isolated CD4þ T cells from OT-II mice in the presence of OVA323
peptide (1mg/mL). After 72 h, cells were harvested and analysed with
flow cytometry.
2.7 Histology
To determine plaque size, cryosections (10 lm) of the aortic root were
stained with Oil-Red-O and haematoxylin (Sigma-Aldrich). Sections with
the largest lesion plus four flanking sections were analysed for lesion size
and two flanking sections for lesion composition. Collagen content in
the lesion was assessed with a Masson’s trichrome staining according to
the manufacturers protocol (Sigma-Aldrich). Corresponding sections on
separate slides were also stained for monocyte/macrophage with a
MOMA-2 antibody (1:1000, AbD Serotec) followed by a goat anti-rat
IgG-alkaline phosphatase antibody (1:100, Sigma-Aldrich). Colour devel-
opment was achieved using nitro blue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate as enzyme substrates. The relative amount
of collagen and percentage of macrophages in the lesions is expressed as
the ratio between the collagen- or MOMA-2-positive and the total lesion
surface area. Smooth muscle cells were stained with an a-smooth
muscle cell-actin (aSMA) antibody (clone 1A4, Sigma-Aldrich) and SMC
positive areas were related to the total intima surface area. The necrotic
core was defined as the a-cellular, debris-rich plaque area as percentage
of total plaque area. CD4þ T cell (RM4-5, 1:90, ThermoFisher) and B cell
(RA3-6B2, 1:100, BD Biosciences) analysis in the lesion was assessed
using a rat monoclonal antibody and a secondary rabbit anti-rat antibody
(BA-4001, Vector). Followed by the Vectastain ABC kit (PK-4000,
Vector) and colour was developed using the ImmPact Novared kit
(Vector). Sections where no primary antibody was used and were taken
as negative controls. All slides were analysed with a Leica DM-RE micro-
scope and LeicaQwin software (Leica Imaging Systems).
For fluorescent histology, cryosections (10 lm) of the spleen were
stained with anti-mouse antibodies against CD3 (SP7) and B220 (RA3-
6B2). Subsequently, sections were stained with secondary goat-anti rab-
bit and goat-anti rat antibodies conjugated to Alexa fluor 647 and Alexa
fluor 488 (Abcam). Nuclei were visualized using the Fluoroshield mount-
ing medium containing DAPI. Sections were captured using a Nikon TiE
2000 confocal microscope with a 20 plan apochromat objective and
analysed with Nis Elements version 4.3.
2.8 Statistics
All data are expressed as mean ± SEM. Data were tested for significance
using a Student’s t-test for two normally distributed groups. Data from
three groups or more were analysed by an ordinary one-way ANOVA
test followed by a Holm–Sidak post hoc test. Data from experiments
with two or more variables were analysed by a two-way ANOVA test
followed by a Sidak post hoc test. P-values of <0.05 were considered sig-
nificant. All statistical analysis was performed using GraphPad Prism 7.0.
3. Results
3.1 B cells from cardiovascular disease
patients display strong BTLA expression
Currently, there is no data available regarding BTLA in patients with car-
diovascular disease (CVD). Hence, we obtained blood and lesions from
patients that underwent an endarterectomy to assess the expression of
BTLA on leucocytes. We found that almost 90% of the circulating
CD19þCD20þ B cells expressed high levels of BTLA, while CD3þ T
cells (8.5%) and monocytes (5.2%) showed a much more moderate ex-
pression and granulocytes expressed only minimal levels of BTLA
(Supplementary material online, Figure SI, Figure 1A and B). Within the le-
sion, the greater majority of leucocytes, including B cells, do not express
BTLA. This is partly caused by a difference in B-cell subsets that reside in
the lesion compared with blood (Figure 1B). The circulating B-cell popu-
lation is mostly composed of naı̈ve B cells that express the highest levels
of BTLA, whereas in the lesion we mainly found effector B-cell subtypes
that have lower BTLA expression. This data suggests that BTLA is most
abundantly expressed on circulating B cells in patients with CVD, while
this expression seems to be lost on B cells that are present in the lesion.
3.2 BTLA is predominantly expressed by
follicular B2 cells in Ldlr/mice
Given the high expression of BTLA on peripheral B cells from CVD
patients and its inhibitory role, we wanted to further explore the poten-
tial of BTLA as a therapeutic target to treat atherosclerosis. First, we
characterized the expression profile of BTLA on immune cells using
spleens from low-density lipoprotein receptor-deficient (Ldlr-/-) mice.
Similar to human leucocytes, we found that BTLA was predominantly
expressed on B cells, with relatively low expression on CD4þ T cells,
CD8þ T cells, and innate immune cells (Figure 2A and Supplementary ma-
terial online, Figure SIIA). Moreover, we did not find any differences in
BTLA expression between CD4þ T helper cell subsets in contrast to
previous work3 (Supplementary material online, Figure SIIB).
Interestingly, we again discovered a significant difference in BTLA expres-
sion between B-cell subsets, with conventional follicular B2 cells being
the most dominant BTLA-expressing leucocyte (Figure 2B).
3.3 BTLA activation reduces initial
atherosclerosis
The role of B cells in atherosclerosis has been quite controversial and
seems to be highly dependent on the B-cell subset.18 Previously, it has
been reported that follicular B-cells aggravate atherosclerosis.19–21 Since
BTLA was most abundantly expressed on follicular B cells, we hypothe-
sized that an agonistic BTLA antibody could inhibit follicular B cells in
Ldlr-/- mice, leading to attenuated atherosclerosis. We therefore treated
female Ldlr-/- mice twice a week with either PBS, an isotype control anti-
body, or an agonistic BTLA antibody (3C10) for 6 weeks while being fed
a WTD (Figure 2C). The 3C10 antibody has previously been described as
a non-depleting agonistic BTLA antibody.15 Treatment with the BTLA
antibody did not affect body weight or total serum cholesterol levels
(Figure 2D and E). Stimulation/agonism of BTLA resulted in a significant
43% reduction in lesion size in the aortic root compared with PBS-
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.treated mice and a significant 37% reduction compared with isotype-
treated mice (Figure 2F). Correspondingly, we found that lesions from
mice treated with the BTLA antibody predominantly consisted of mac-
rophages and relatively low amounts of collagen (Supplementary mate-
rial online, Figure SIII), illustrating an early lesion phenotype. In contrast,
lesions from mice treated with PBS or the isotype control, showed a
more advanced phenotype with relatively more collagen and less macro-
phage content (Supplementary material online, Figure SIII).
3.4 Activation of BTLA leads to strong
follicular B2 cell reduction
To assess whether the reduced atherosclerosis could be attributed to al-
tered immune functions, we analysed circulating leucocytes. We found a
major reduction in total white blood cells in mice treated with the BTLA
antibody compared with PBS- or isotype-treated mice (Supplementary
material online, Figure SIV). This was primarily due to a major decrease in
lymphocytes and a smaller decrease in monocytes. Since monocytes and
macrophages contribute significantly to initial lesion formation, we mea-
sured monocytes and monocyte subsets with flow cytometry but we
could not identify a difference between BTLA-treated mice and PBS- or
isotype-treated mice (Supplementary material online, Figure SV). The
strong lymphocyte reduction was primarily due to a sharp decrease in B
cells in the blood and a similar effect was found in the spleen, lymph
node, and peritoneum (Figure 3A, Supplementary material online, Figure
SVIA). Moreover, analysis of the B cell lineages showed that BTLA ago-
nism particularly led to a reduction in B2 cells and a relative increase in
the percentage of B1 cells (Figure 3B, Supplementary material online,
Figure SVIB). More specifically, we found that the percentage of follicular
B2 cells decreased, while marginal zone B cells increased in mice treated
with the BTLA antibody compared with mice treated with PBS or iso-
type control (Figure 3C, Supplementary material online, Figure SVIC). In
line with these findings, fluorescent immunohistology on spleen cryosec-
tions revealed that BTLA stimulation led to a decrease of B cells immedi-
ately surrounding the T cell areas, which corresponds to a reduction in
follicular B cells (Figure 3D).
Mechanistically, we show that BTLA agonism, similarly as BTLA-
HVEM signalling, increased apoptosis and reduced activation in follicular
B cells (Supplementary material online, Figure SVII). Since follicular B cells
are often involved in the humoral immunity, we next determined
whether BTLA treatment reduced atherosclerosis by altering antibody
responses. However, we did not find relevant differences in either total
or malondialdehyde-LDL and oxidized-LDL-specific serum titer levels
that could explain the ameliorated atherosclerosis (Supplementary ma-
terial online, Figure SVIII).
Figure 1 B cells from CVD patients display strong BTLA expression. Flow cytometry was applied on blood and lesions from CVD patients to identify
BTLA expression on major leucocyte populations. (A) A flowcharts of BTLA expression by major leucocyte populations. (B) Quantification of BTLA expres-
sion by leucocyte populations and B-cell subsets. A two-way ANOVA followed by a Sidak post hoc test was performed. Data are shown as mean ± SEM, n =
11 (*P<0.05, **P<0.01, ****P<0.0001 vs. isotype).
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3.5 Activation of BTLA leads to increased
regulatory B cells
Besides the conventional B1 and B2 cells, we nowadays know that there
are many novel B-cell subsets that can regulate the immune response.18
Although most of these regulatory B cells (Bregs) ultimately act via
interleukin-10 (IL-10), they can be identified by different extracellular
markers,22 such as CD1dhiCD5þ expression,23 and T-cell immunoglobu-
lin and mucin domain 1 (TIM-1).24 We found that BTLA was expressed
on all of these Breg subsets (Supplementary material online, Figure SIIC).
Accordingly, Ldlr-/- mice treated with agonistic BTLA showed a very
strong increase in B10 cells and TIM-1þ B cells in the spleen, lymph
nodes, and blood when compared with treatment with PBS or isotype
control (Figure 4A and B). In addition, we measured the direct secretion
of IL-10 by B cells and found that BTLA stimulation significantly increased
the percentage of B cells that secreted IL-10 compared with the PBS or
isotype control groups (Figure 4C).
3.6 Activation of BTLA leads to a
protective T-cell response
Treatment with the BTLA antibody resulted in a B cell pool that is highly
enriched in marginal zone B cells and Breg cells, which can both inhibit
the CD4þ T-cell response.22,25 Hence, we assessed the number of
lesional CD4þ T cells and found a marked reduction in infiltrating CD4þ
T cells in BTLA-treated mice compared with PBS- or isotype-treated
mice (Figure 5A). Corroborating with earlier data,21 we did not find any
relevant numbers of B cells in the lesion at this stage (Supplementary ma-
terial online, Figure SIX). We thus reasoned that the CD4þ T-cell regula-
tion had taken place peripherally as shown in earlier reports.21 Although
we did not find a difference in total splenic CD4þ T cells, we found that
BTLA-treated mice contained more effector and less naı̈ve T cells than
PBS- or isotype-treated mice (Figure 5B). More specifically, we observed
an increase in regulatory (Treg) and Th17 cells in BTLA-treated mice,
while no effects were found for Th1 or Th2 cells (Figure 5C). It is widely
recognized that Tregs are atheroprotective26 and Th17 cells have also
been shown to protect against atherosclerosis in a setting with reduced
B cells.21 This indicates that treatment with the BTLA antibody polarized
the CD4þ T-cell response in vivo towards a more atheroprotective
response. The reduced activation of CD4þ T cells in BTLA-treated mice
was not dependent on changes in DCs, as we did not find differences in
total DCs or regulatory DCs (DEC-205þCD8þ) between PBS-, isotype-,
or BTLA-treated mice (Supplementary material online, Figure SX).
To test if the altered CD4þ T-cell response after BTLA treatment was a
direct effect of a different B cell pool, we cultured OT-II CD4þ T cells
with B cells from mice treated with PBS or the BTLA antibody. We
found that after 72 h of stimulation with OVA323 peptide, OT-II CD4þ
T-cells cultured in the presence of BTLA-treated B cells, showed a
Figure 2 Activation of BTLA reduces initial atherosclerosis. (A) Flow overlays and quantification of BTLA expression in leucocyte populations and (B) spe-
cific B-cell subsets of female Ldlr-/- mice; follicular (CD21intCD23þ); marginal zone (CD21hiCD23-) and newly formed (CD23loCD21lo). (C) Female Ldlr-/-
mice were treated twice a week intraperitoneally with PBS, an isotype antibody, or an agonistic BTLA antibody for 6 weeks, while being fed a western-type
diet. (D) Mice were weighed and (E) serum cholesterol levels were determined. (F) Oil-Red-O and haematoxylin staining in aortic root sections and lesion
size quantification. Scale bars are 100 mm. An ordinary one-way ANOVA test followed by a Holm–Sidak post hoc test was performed. Data are shown as
mean ± SEM, n = 3 (A/B) and n = 9/12 (C–F) (*P<0.05, **P < 0.01, ****P < 0.0001).
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Figure 3 Activation of BTLA leads to strong follicular B2 cell reduction. Female Ldlr-/- mice were treated twice a week with PBS, an isotype antibody, or
an agonistic BTLA antibody and fed a WTD for 6 weeks. (A) A flowcharts of splenocytes and quantifications of B cells (CD19þB220þ) in different organs.
(B) A flowcharts of splenocytes and quantification of B1 cells (CD19þCD11bþB220lo) and B2 cells (CD19þCD11b-B220þ) in the spleen. (C) A flowcharts
of splenocytes and quantification of follicular (CD21intCD23þ), marginal zone (CD21hiCD23-), and newly formed (CD23loCD21lo) B cells in the spleen. (D)
Representative images of spleen sections stained for CD3 (red), B220 (green), and DAPI (blue). Regions of interest are visualized as depicted at higher mag-
nifications. Scale bars are 100 mm and 500 mm. An ordinary one-way ANOVA test followed by a Holm–Sidak post hoc test was performed. Data are shown
as mean ± SEM, n = 11–12 (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
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marked increase in Tregs (Figure 5D). Moreover, CD4þ T cells from co-
cultures with BTLA-treated B cells showed a significant decrease
in TNFa secretion, while IL-5 secretion was increased compared with
T cells from co-cultures with PBS-treated B cells (Figure 5E). Finally,
we show that the anti-inflammatory T-cell response seen with BTLA
agonism was not exclusively caused by changes seen in B cells, as
BTLA treatment in B cell depleted mice also inhibits TNFa secretion by
CD4þ T cells (Supplementary material online, Figure SXI).
Taken together, these data strongly indicate that the BTLA antibody
reduced the peripheral activation of CD4þ T cells, both indirectly by al-
tering the APC function of B cells and by directly polarizing CD4þ T
cells, resulting in reduced lesional CD4þ T cells.
3.7 Activation of BTLA enhances collagen
content in established lesions
Since most CVD patients that require medication already have well-
established atherosclerosis, we also investigated the effects of the BTLA
antibody on pre-existing lesions. Therefore, we fed Ldlr-/- mice a WTD
for 10 weeks, after which we started the agonistic BTLA or isotype treat-
ment for 6 weeks (Figure 6A). In line with our initial atherosclerosis study,
we found a highly significant reduction in total B cells in all relevant
organs (Figure 6B) caused by a strong decrease in follicular B cells (Figure
6C). In contrast, IL-10þ B cells (Figure 6D) and Tregs were increased
(Supplementary material online, Figure SXII). Although we did not find dif-
ferences in lesion size between isotype- or BTLA-treated mice (Figure
6E), we did observe that lesions of mice treated with the BTLA antibody
contained significantly more collagen than lesions of mice treated with
the isotype control (Figure 6F). Furthermore, lesional macrophages,
smooth muscle cell content, and necrotic core area was determined
(Supplementary material online, Figure SXIII).
Discussion
The discovery of immune checkpoint proteins has been a tremendous
support in finding targets for immunomodulatory drugs.2 For many of
these co-receptors, therapeutic antibodies or small molecules are now
being tested in experimental animal models or in clinical trials. For the
treatment of atherosclerosis and CVD, we still lack potent agents that
target pathways other than cholesterol metabolism. There is an urgent
need for such treatments, since the residual risk of CVD is still consider-
able even after effective cholesterol management.27 Moreover, the re-
cent CANTOS trial demonstrated that anti-inflammatory therapy can
significantly reduce the risk of cardiovascular events.28 In this study, we
provide the first evidence that one of the newest additions to the co-
receptor family, BTLA, is a very promising target for the treatment of
atherosclerosis.
Figure 4 Activation of BTLA leads to increased regulatory B cells. Female Ldlr-/- mice were treated twice a week with PBS, an isotype antibody, or an ago-
nistic BTLA antibody and fed a WTD for 6 weeks. A flowcharts for splenocytes and quantifications of regulatory B cells are shown for (A) B10 cells
(CD19þCD1dhiCD5þ), (B) TIM-1þ B cells (CD19þTIM-1þ), and (C) IL-10 secreting B cells (CD19þIL-10þ). An ordinary one-way ANOVA test followed by
a Holm–Sidak post hoc test was performed. Data are shown as mean ± SEM, n = 11–12 (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).







niversiteit Leiden / LU
M
C





















..Up to date, most research in relation to BTLA has focused on T cells,
while it is most abundantly expressed on B cells.3,6,29,30 One apparent
reason for this discrepancy could be that many inflammatory disorders
are thought to be mainly T-cell driven. However, with the recognition of
novel B-cell subsets, we gained significantly more insight into the actual
contribution of B cells to inflammatory disorders. In atherosclerosis, we
now know that B1 cells,19,31 marginal zone B cells,25 and regulatory B
cells32 can exert protective functions, contrary to follicular B cells that
aggravate atherosclerosis.20,21 Since follicular B cells are in the majority,
complete B2 cell depletion has resulted in attenuated atherosclero-
sis.20,21 Yet, these treatments deplete the complete B2 cell population
which includes atheroprotective Bregs and marginal zone B cells.20,21,33
In a side-to-side comparison study, we show that whereas anti-CD20
treatment depletes all B cells, BTLA specifically targets follicular B2 cells
and can directly inhibit pro-inflammatory CD4þ T cells. Secondly, the
humoral immunity is compromised with complete B2 cell depletion, il-
lustrated by reductions in both total and antigen-specific IgG and IgM
antibodies.20,21 In this study, we now describe that an agonistic antibody
for BTLA specifically reduced, but not ablated, the atherogenic follic-
ular B cells, while the atheroprotective B-cell subsets were increased.
Although B cell depleting antibodies are already in clinical use for
other autoimmune diseases such as rheumatoid arthritis,34 we be-
lieve that BTLA stimulation might be superior to total B-cell deple-
tion in CVD. However, to confirm this, future atherosclerosis studies
comparing agonistic BTLA treatment with total B-cell depletion
should be performed.
Figure 5 Activation of BTLA leads to decreased T-cell infiltration and activation. Female Ldlr-/- mice were treated twice a week intraperitoneally with PBS,
an isotype antibody, or an agonistic BTLA antibody for 6 weeks while being fed a western-type diet. (A) Representative images of aortic root sections stained
for CD4 (arrows) and haematoxyline and cell number quantification. Scale bars are 100 mm. (B) A flowcharts and quantifications of total CD4þ T cells, naive
CD4þ T cells (CD62lþCD44-), effector CD4þ T cells (CD62l-CD44þ), and effector memory CD4 T cells (CD62lþCD44þ) in splenocytes. (C) Flow cytom-
etry quantifications of regulatory T cells (FoxP3þ), Th17 (RORytþ), Th1 (T-betþ), and Th2 (Gata-3þ) cells in splenocytes. (D) B cells from mice treated with
PBS or an agonistic BTLA antibody for 2 weeks were co-cultured with isolated CD4þ T cells from OTII mice in the presence of OVA323 peptide (1 mg/mL).
CD4þ T cells were harvested after 72 h and assessed with flow cytometry for regulatory T cells (FoxP3þ), Th17 (RORytþ), Th1 (T-betþ), and Th2 (Gata-
3þ) cells and (E) for cytokine production. An ordinary one-way ANOVA test followed by a Holm–Sidak post hoc test was performed. Data are shown as
mean ± SEM, n = 9/12 (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.00001). Tregs, regulatory T cells; Th, T helper cell.
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..Additionally, we have found that the humoral immunity was not
affected since both total and antigen-specific IgG1, IgG2, and IgM
levels remained the same. This is in line with others that showed
that blockade of the HVEM/BTLA pathway also did not alter the hu-
moral effect following transplantation.35 This highlights the potential
benefits of using an agonistic BTLA antibody for the treatment of
atherosclerosis.
Besides reducing atherogenic follicular B2 cells, we found that
BTLA activation resulted in a splenic B-cell population enriched in
atheroprotective marginal zone B cells and Bregs. Bregs have shown
great protective potential in autoimmune disorders such as collagen-
induced arthritis and experimental autoimmune encephalomyelitis,
primarily through their production of IL-10.22 Studies investigating
the role of Bregs in atherosclerosis show conflicting results.18,32,36
However, recently, we found a very strong inverse correlation
between atherosclerosis severity and the frequency of IL-10þ B cells,
and adoptive transfer of IL-10þ B cells strongly reduced circulating
leucocyte numbers and inflammatory monocytes in Ldlr-/- mice37
Moreover, blockade of TIM-1, another immune checkpoint protein
strongly associated with increased IL-10 producing B cells,24 leads
to aggravated atherosclerosis, potentially via the blockade of TIM-1þ
B cells.38 Since BTLA agonism strongly increased B10 cells and
TIM-1þ B cells, we believe this contributed to the reduction of
atherosclerosis.
In the last years, it has been increasingly recognized that B cells have
an important cellular function independent of antibody production. We
found that the altered B-cell population led to strongly decreased T-cell
activation. In addition, we showed that in both atherosclerosis studies
Figure 6 Activation of BTLA enhances collagen content in established lesions. (A) Female Ldlr-/- mice were fed a WTD for 10 weeks after which one
group was sacrificed (baseline), while other mice were treated twice a week intraperitoneally with an isotype antibody or an agonistic BTLA antibody for 6
weeks. (B) Flow cytometry quantification of B cells (CD19þ) in different organs. (C) A flowcharts of splenocytes and quantification of follicular
(CD21intCD23þ), marginal zone (CD21hiCD23-), and newly formed (CD23loCD21lo) B cells in the spleen. (D) Flow cytometry quantification of regulatory
B cells (CD19þIL-10þ) in spleen and lymph node. (E) Oil-Red-O and haematoxylin staining in aortic root sections and lesion size quantification. (F)
Trichrome staining in aortic root sections and collagen quantification. Scale bars are 100 mm. A Student’s t-test was performed for two groups or an ordinary
one-way ANOVA test followed by a Holm–Sidak post hoc test for multiple groups. Data are shown as mean ± SEM n = 11–12 (*P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001).
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and in the B-T cell co-cultures, BTLA activation resulted in increased
Tregs. During many autoimmune disorders, including atherosclerosis,
Tregs become dysfunctional and are unable to curb disease.26
Restoration of this function or expansion of Tregs has been protective in
atherosclerosis.26 Interestingly, it has previously been demonstrated that
in experimental autoimmune encephalomyelitis, Bregs are able to re-
cover the inhibitory activity of Tregs in a BTLA-dependent manner.39
Enhanced inhibitory activity of Tregs, could also explain the decrease in
T-cell activation found in this study. In our B–T-cell co-cultures, we
show BTLA activation promotes an increase in IL-5, which has been
shown to induce Tregs40 and a decrease in the pro-inflammatory cyto-
kine TNFa, which further support a decrease in inflammatory response
after BTLA activation. Furthermore, we show that the BTLA antibody
also directly inhibits pro-inflammatory T cells under hypercholesterolae-
mic conditions. Overall, the expansion of Bregs and Tregs could have
greatly contributed to the atheroprotective effects found with BTLA ac-
tivation. Future studies employing mice deficient for Tregs or B cells
could provide more mechanistic insights into the atheroprotective effect
of BTLA agonism.
Nowadays, tremendous efforts are undertaken in the clinic to identify
and treat vulnerable lesions that are prone to rupture.41 By stimulating
the BTLA pathway we were able to both reduce lesion size in an initia-
tion study and also enhance collagen content, an important feature of
stable lesion, during progression of atherosclerosis. The latter under-
scores that modulating the BTLA pathway presents a very promising op-
tion for clinical use. In addition, we found that in CVD patients almost
90% of all circulating B cells still express high levels of BTLA. Despite our
limited sample number, this suggests that BTLA is also an interesting and
accessible target in CVD patients.
In summary, treatment with an agonistic BTLA antibody prevents ath-
erosclerosis and increases collagen content in already established lesions
by favourably shifting the balance between atherogenic follicular B cells
and atheroprotective B cells and directing CD4þ T cells towards Tregs.
Our data strongly indicate that BTLA activation may be considered for
the treatment of atherosclerosis.
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Supplementary material is available at Cardiovascular Research online.
Acknowledgements
We thank Maria Ozsvar Kozma for her technical assistance with the anti-
body measurements.
Conflict of interest: none declared.
Funding
This work was supported by the European Union’s Seventh Framework
[603131 to J.K.], by contributions from Academic and SME/industrial
partners and supported by the Netherlands Heart Foundation
[2016T008 to A.C.F.].
References
1. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in ath-
erosclerosis: from mice to humans. Immunity 2013;38:1092–1104.
2. Foks AC, Kuiper J. Immune checkpoint proteins: exploring their therapeutic potential
to regulate atherosclerosis. Br J Pharmacol 2017;174:3940–3955.
3. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA,
Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM. BTLA
is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat
Immunol 2003;4:670–679.
4. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S, Pfeffer
K, Ware CF, Murphy TL, Murphy KM. B and T lymphocyte attenuator regulates T
cell activation through interaction with herpesvirus entry mediator. Nat Immunol
2005;6:90–98.
5. Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J. An inhibitory Ig superfamily pro-
tein expressed by lymphocytes and APCs is also an early marker of thymocyte posi-
tive selection. J Immunol 2004;172:5931–5939.
6. Krieg C, Han P, Stone R, Goularte OD, Kaye J. Functional analysis of B and T lym-
phocyte attenuator engagement on CD4þ and CD8þ T cells. J Immunol 2005;175:
6420–6427.
7. Oya Y, Watanabe N, Owada T, Oki M, Hirose K, Suto A, Kagami S-I, Nakajima H,
Kishimoto T, Iwamoto I, Murphy TL, Murphy KM, Saito Y. Development of autoim-
mune hepatitis-like disease and production of autoantibodies to nuclear antigens in
mice lacking B and T lymphocyte attenuator. Arthritis Rheum 2008;58:2498–2510.
8. Wang X-F, Chen Y-J, Wang Q, Ge Y, Dai Q, Yang K-F, Zhou Y-H, Hu Y-M, Mao Y-
X, Zhang X-G. Distinct expression and inhibitory function of B and T lymphocyte at-
tenuator on human T cells. Tissue Antigens 2007;69:145–153.
9. Oki M, Watanabe N, Owada T, Oya Y, Ikeda K, Saito Y, Matsumura R, Seto Y,
Iwamoto I, Nakajima H. A functional polymorphism in B and T lymphocyte attenua-
tor is associated with susceptibility to rheumatoid arthritis. Clin Dev Immunol 2011;
2011:305656.
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